|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:George_Scangos
gptkb:Marianne_De_Backer
|
|
gptkbp:clinicalTrialPhase
|
COMET-ICE
COMET-PEAK
COMET-TAIL
|
|
gptkbp:collaboratedWith
|
gptkb:Alnylam_Pharmaceuticals
gptkb:Biogen
gptkb:Bill_&_Melinda_Gates_Foundation
GlaxoSmithKline
|
|
gptkbp:focus
|
immunology
infectious diseases
|
|
gptkbp:founded
|
2016
|
|
gptkbp:founder
|
gptkb:George_Scangos
gptkb:Robert_Nelsen
|
|
gptkbp:headquartersLocation
|
gptkb:San_Francisco,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vir Biotechnology, Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:IPODate
|
October 2019
|
|
gptkbp:mission
|
to address and treat serious infectious diseases
|
|
gptkbp:notableAchievement
|
developed COVID-19 monoclonal antibody therapy
|
|
gptkbp:notableProduct
|
gptkb:sotrovimab
VIR-2218
VIR-2482
VIR-7831
|
|
gptkbp:numberOfEmployees
|
~400 (2023)
|
|
gptkbp:product
|
gptkb:sotrovimab
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:servesArea
|
global
|
|
gptkbp:stockSymbol
|
gptkb:NASDAQ
VIR
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.vir.bio/
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ:VIR
|
|
gptkbp:bfsLayer
|
7
|